Published in J Gastrointest Oncol on March 01, 2013
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 18.26
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 5.68
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol (2010) 5.10
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res (2002) 4.46
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood (2003) 3.86
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer (2007) 3.61
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab (2008) 3.38
Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov (2004) 3.25
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res (2006) 2.84
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer (2008) 2.68
Hypoxia-responsive transcription factors. Pflugers Arch (2005) 2.64
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene (2003) 2.56
New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40
The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer (2001) 2.36
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res (2009) 2.25
Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst (1995) 2.24
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res (2011) 2.22
Genetic knockouts and knockins in human somatic cells. Nat Protoc (2007) 2.21
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J (2000) 2.17
BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J (2008) 2.06
Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One (2009) 1.90
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res (2005) 1.71
BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol (2004) 1.71
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer (2006) 1.68
Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res (2001) 1.67
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res (2007) 1.56
BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer (2011) 1.47
Mutation scanning using high-resolution melting. Biochem Soc Trans (2009) 1.38
Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev (2008) 1.36
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res (2009) 1.35
Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol (2008) 1.34
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.31
PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat (2008) 1.29
Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer (2004) 1.28
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer (2011) 1.27
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One (2011) 1.27
Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut (2006) 1.25
Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer (2004) 1.18
Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res (2009) 1.10
Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials (2007) 1.04
Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol (2011) 1.00
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep (2010) 0.98
Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm. Mol Diagn Ther (2006) 0.97
Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. Ann Surg Oncol (2006) 0.92
CIMPle origin for promoter hypermethylation in colorectal cancer? Nat Genet (2006) 0.88
Trial offers early test case for personalized medicine. J Natl Cancer Inst (2009) 0.85
Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients. Mol Biol Rep (2011) 0.83
The strength of European oncology. Eur J Cancer (2008) 0.76
Heritable individual-specific and allele-specific chromatin signatures in humans. Science (2010) 5.94
Open chromatin defined by DNaseI and FAIRE identifies regulatory elements that shape cell-type identity. Genome Res (2011) 4.43
Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol (2009) 2.68
Large-area vapor-phase growth and characterization of MoS(2) atomic layers on a SiO(2) substrate. Small (2012) 2.66
RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature (2012) 2.11
XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology (2010) 2.08
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
Direct laser writing of micro-supercapacitors on hydrated graphite oxide films. Nat Nanotechnol (2011) 2.02
Single-atom catalysis of CO oxidation using Pt1/FeOx. Nat Chem (2011) 1.98
A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat Nanotechnol (2009) 1.94
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis (2011) 1.91
Ultra-stable nanoparticles of CdSe revealed from mass spectrometry. Nat Mater (2004) 1.86
Vapour phase growth and grain boundary structure of molybdenum disulphide atomic layers. Nat Mater (2013) 1.83
Schistosomiasis control in China: the impact of a 10-year World Bank Loan Project (1992-2001). Bull World Health Organ (2005) 1.80
Graphene quantum dots derived from carbon fibers. Nano Lett (2012) 1.79
A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A (2006) 1.78
Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proc Natl Acad Sci U S A (2009) 1.71
A conserved ubiquitination pathway determines longevity in response to diet restriction. Nature (2009) 1.71
Synthesis and characterization of chiral mesoporous silica. Nature (2004) 1.66
Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J Biol Chem (2011) 1.58
Cell-type specific and combinatorial usage of diverse transcription factors revealed by genome-wide binding studies in multiple human cells. Genome Res (2011) 1.53
A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer (2010) 1.46
Localization of an NH(2)-terminal disease-causing mutation hot spot to the "clamp" region in the three-dimensional structure of the cardiac ryanodine receptor. J Biol Chem (2007) 1.43
Complex zeolite structure solved by combining powder diffraction and electron microscopy. Nature (2006) 1.43
Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol (2004) 1.40
Intrinsic structural defects in monolayer molybdenum disulfide. Nano Lett (2013) 1.38
Visualizing and identifying single atoms using electron energy-loss spectroscopy with low accelerating voltage. Nat Chem (2009) 1.34
Growth of bilayer graphene on insulating substrates. ACS Nano (2011) 1.33
Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol (2015) 1.33
Large-pore apertures in a series of metal-organic frameworks. Science (2012) 1.29
Gated tunability and hybridization of localized plasmons in nanostructured graphene. ACS Nano (2013) 1.27
A stable cathode for the aprotic Li-O2 battery. Nat Mater (2013) 1.26
Sulfur-doped graphene as an efficient metal-free cathode catalyst for oxygen reduction. ACS Nano (2011) 1.25
MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett (2013) 1.24
Graphene-antenna sandwich photodetector. Nano Lett (2012) 1.24
Three-dimensional localization of serine 2808, a phosphorylation site in cardiac ryanodine receptor. J Biol Chem (2007) 1.24
Active tunable absorption enhancement with graphene nanodisk arrays. Nano Lett (2013) 1.23
Encapsulation of single enzyme in nanogel with enhanced biocatalytic activity and stability. J Am Chem Soc (2006) 1.21
Short-term memory trace in rapidly adapting synapses of inferior temporal cortex. PLoS Comput Biol (2008) 1.20
Exploring the mechanism of Physcomitrella patens desiccation tolerance through a proteomic strategy. Plant Physiol (2009) 1.19
An enterovirus 71 epidemic in Guangdong Province of China, 2008: epidemiological, clinical, and virogenic manifestations. Jpn J Infect Dis (2011) 1.19
Visualization of uncorrelated, tandem symmetry mismatches in the internal genome packaging apparatus of bacteriophage T7. Proc Natl Acad Sci U S A (2013) 1.19
Three-dimensional localization of divergent region 3 of the ryanodine receptor to the clamp-shaped structures adjacent to the FKBP binding sites. J Biol Chem (2003) 1.17
Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval. J Gastroenterol Hepatol (2007) 1.17
Guidance-cue control of horizontal cell morphology, lamination, and synapse formation in the mammalian outer retina. J Neurosci (2012) 1.17
The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat (2010) 1.17
Graphene oxide: structural analysis and application as a highly transparent support for electron microscopy. ACS Nano (2009) 1.16
Cleome, a genus closely related to Arabidopsis, contains species spanning a developmental progression from C(3) to C(4) photosynthesis. Plant J (2007) 1.16
Organic topological insulators in organometallic lattices. Nat Commun (2013) 1.14
Bis(2,4-dibromo-6-formyl-phenolato-κO,O')copper(II). Acta Crystallogr Sect E Struct Rep Online (2007) 1.13
Three-dimensional metal-graphene-nanotube multifunctional hybrid materials. ACS Nano (2012) 1.13
On and off retinal circuit assembly by divergent molecular mechanisms. Science (2013) 1.12
A novel PRPF31 splice-site mutation in a Chinese family with autosomal dominant retinitis pigmentosa. Mol Vis (2004) 1.11
High-resolution mapping of h1 linker histone variants in embryonic stem cells. PLoS Genet (2013) 1.11
Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol (2012) 1.10
Expression of p53 isoforms in renal cell carcinoma. Chin Med J (Engl) (2009) 1.08
Bottom-up approach toward single-crystalline VO2-graphene ribbons as cathodes for ultrafast lithium storage. Nano Lett (2013) 1.08
Twisting bilayer graphene superlattices. ACS Nano (2013) 1.08
MRG-1, an autosome-associated protein, silences X-linked genes and protects germline immortality in Caenorhabditis elegans. Development (2007) 1.06
Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas. J Cancer Res Clin Oncol (2008) 1.05
Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor. J Biol Chem (2011) 1.05
Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer. Oncol Rep (2009) 1.04
A graph theory method for determination of cryo-EM image focuses. J Struct Biol (2012) 1.04
CLIC2-RyR1 interaction and structural characterization by cryo-electron microscopy. J Mol Biol (2009) 1.04
Tunable band gap photoluminescence from atomically thin transition-metal dichalcogenide alloys. ACS Nano (2013) 1.03
Plasmonic hot electron induced structural phase transition in a MoS2 monolayer. Adv Mater (2014) 1.03
Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes. J Biol Chem (2012) 1.02
Localization of PKA phosphorylation site, Ser(2030), in the three-dimensional structure of cardiac ryanodine receptor. Biochem J (2008) 1.02
TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production. BMC Biol (2012) 1.01
Kidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats. Biomed Res Int (2013) 1.01
Analysis of host-inducing proteome changes in bifidobacterium longum NCC2705 grown in Vivo. J Proteome Res (2007) 1.00
Thickness-dependent morphologies of gold on n-layer graphenes. J Am Chem Soc (2010) 1.00
Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int J Oncol (2006) 1.00
Nanoparticle tension probes patterned at the nanoscale: impact of integrin clustering on force transmission. Nano Lett (2014) 1.00
Plasmon-induced doping of graphene. ACS Nano (2012) 1.00
NKT TCR recognition of CD1d-α-C-galactosylceramide. J Immunol (2011) 0.99
GM-CSF contributes to aortic aneurysms resulting from SMAD3 deficiency. J Clin Invest (2013) 0.99
Quantum anomalous Hall effect in 2D organic topological insulators. Phys Rev Lett (2013) 0.99
Coaxially stacked coronene columns inside single-walled carbon nanotubes. Angew Chem Int Ed Engl (2011) 0.98
Shigella flexneri T3SS effector IpaH4.5 modulates the host inflammatory response via interaction with NF-κB p65 protein. Cell Microbiol (2012) 0.98
Building 3D structures of vanadium pentoxide nanosheets and application as electrodes in supercapacitors. Nano Lett (2013) 0.98
Elevated mean platelet volume is associated with presence of colon cancer. Asian Pac J Cancer Prev (2014) 0.98
MicroRNA-93 suppress colorectal cancer development via Wnt/β-catenin pathway downregulating. Tumour Biol (2014) 0.97
(3,5-Dichloro-salicylaldehyde thio-semi-carbazonato-κS,N,O)(N,N'-dimethyl-formamide-κO)copper(II) dimethyl-formamide solvate. Acta Crystallogr Sect E Struct Rep Online (2008) 0.97
Selection and validation of suitable reference genes for miRNA expression normalization by quantitative RT-PCR in citrus somatic embryogenic and adult tissues. Plant Cell Rep (2012) 0.97
Tunable electronics in large-area atomic layers of boron-nitrogen-carbon. Nano Lett (2013) 0.97
[Study on objectively evaluating skin aging according to areas of skin texture]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi (2015) 0.96
Myocardium-targeted transplantation of mesenchymal stem cells by diagnostic ultrasound-mediated microbubble destruction improves cardiac function in myocardial infarction of New Zealand rabbits. Int J Cardiol (2009) 0.96
Direct laser-patterned micro-supercapacitors from paintable MoS2 films. Small (2013) 0.96
Nanoparticulate TiO2(B): an anode for lithium-ion batteries. Angew Chem Int Ed Engl (2012) 0.95
Calmodulin-binding locations on the skeletal and cardiac ryanodine receptors. J Biol Chem (2012) 0.95
Band gap engineering and layer-by-layer mapping of selenium-doped molybdenum disulfide. Nano Lett (2013) 0.94
Type I interferons in Sjögren's syndrome. Autoimmun Rev (2012) 0.94
Diagnostic significance of blood eosinophil count in eosinophilic chronic rhinosinusitis with nasal polyps in Chinese adults. Laryngoscope (2012) 0.94
Catalyst and chirality dependent growth of carbon nanotubes determined through nano-test tube chemistry. Adv Mater (2010) 0.94
Effect of raw material ratios on the compressive strength of magnesium potassium phosphate chemically bonded ceramics. Mater Sci Eng C Mater Biol Appl (2013) 0.94
[The prevalence of HIV infection and the risk factors among MSM in 4 cities, China]. Zhonghua Yu Fang Yi Xue Za Zhi (2010) 0.94
MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D. Pigment Cell Melanoma Res (2014) 0.93
Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer (2014) 0.93
How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation. Biochemistry (2011) 0.93